“Effect of Hormone Resistance Type on First-Line Treatment Selection in ER+ HER2-Negative Metastatic Breast Cancer”. 2026. Voprosy Onkologii 72 (3): OF-2675. https://doi.org/10.37469/0507-3758-2026-72-3-OF-2675.